Research programme: cannabinoid receptor CB2 agonists - Amgen

Drug Profile

Research programme: cannabinoid receptor CB2 agonists - Amgen

Latest Information Update: 06 Apr 2011

Price : $50

At a glance

  • Originator Amgen
  • Class Oxadiazoles; Piperidines
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 04 Sep 2008 Preclinical trials in Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top